.png){kind=logo}
WHY IT MATTERS
Failure to meet enrollment timelines:
-
Delays delivery of therapies to patients in need
-
Puts millions of dollars at risk via impacts to trial budgets
-
Affects long-term profitability
CHALLENGE #6
Clinical Trial Recruitment
Identifying PIs and HCPs who can refer patients for trial participation is a "significant to very significant challenge" for 57% of pharmaceutical companies.
While 71% of sites conduct HCP outreach to facilitate referrals, this action drives less than 20% of patient enrollment.2
What’s behind the challenge?
-
A focus on academic institutions/urban areas and HCPs that are overtaxed with clinical trials
- Inability to see HCPs' referral networks and patient population demographics
-
Lack of visibility into each HCP’s recent and current trial participation to assess receptivity to a new trial
-
Inefficient, “cast-a-wide-net” approach to patient recruitment
-
Not using AI-powered alerts to drive engagement at the most relevant point in the patient journey